ProstaGene

ProstaGene is a biotechnology start up company that is developing technology based on patents of the Founder, Dr. Richard G. Pestell. ProstaGene LLC integrates proprietary molecular diagnostics with novel therapeutic screening and commercial experience in order to develop novel treatments for cancer. The company has developed a diagnostic test that distinguishes benign from malignant prostate cancer with a predictive value of >98% in two retrospective clinical studies. The company has developed a prognostic test that defines a group of patients with poor outcome based on a signature of gene expression in the patients prostate tumor. The company has developed a novel platform for preclinical testing of therapies for metastatic prostate cancer in immune competent mice. The company has identified a therapeutic for metastatic prostate cancer that has shown to be highly effective in preclinical testing.

Website

http://prostagene.com

External link for ProstaGene

Industry

Biotechnology

Company size

11-50 employees

Headquarters

Wynnewood, PA

Type

Privately Held

Founded

2010

Specialties

biotechnology, cancer, prostate cancer, and diagnostic testing